UTMOVE Clinical Research

UTMOVE offers leading-edge observational and interventional studies. We hope to understand more about the underlying mechanisms of disease and develop novel disease-modifying therapies for movement disorders through research.

Some of our current trials include:

Parkinson’s Disease

https://www.youtube.com/watch?v=PqVj-Axdh5I

MSC-II: Placebo-controlled trial of allogeneic bone marrow-derived mesenchymal stem cell as a disease-modifying therapy for Parkinson’s disease.
FMT: Placebo-controlled trial of fecal microbiome transplant as a therapy for Parkinson disease.
CVL-751-PD-001: Placebo-controlled trial on the use of Tavapadon as monotherapy early in Parkinson’s disease
CVL-751-PD-002: Placebo-controlled trial on the use of Tavapadon as add therapy in advanced in Parkinson’s disease.
Neuroinflammation in Parkinson’s disease: an observational study that explores the immune system’s role in the pathogenesis of Parkinson’s disease.

For more information about these trials, please contact Vanessa.K.Thyne@uth.tmc.edu or 713-500-7127.

Huntington’s Disease

https://www.youtube.com/watch?v=as4M8ln_CCc

Generation HD1: an interventional disease modifying trial studying the efficacy of an antisense oligonucleotide in individuals with HD
Enroll-HD: observational study looking at various qualities of patients with Huntington’s Disease.

KINECT-HD: clinical trial studying the efficacy of valbenazine for the treatment of chorea associated with Huntington’s disease.
CHANGE-HD: an observational study evaluating patients at risk for developing Huntington’s disease from 6-30 years old to better understand the developing brain in at risk individuals.
Irritability in HD: clinical trial evaluating the efficacy of Nuedexta for the treatment of irritability in patients with Huntington’s disease.
Sleep Disorders in HD: clinical trial evaluating the efficacy of Melatonin for the management of sleep problems in patients with Huntington’s disease.
HD-Clarity: an observational study to evaluate biomarkers in cerebrospinal fluid of patients with Huntington’s disease.
uniQure: clinical trial looking to demonstrate the safety and tolerability of AMT-130 when delivered directly to the brain of patients with Huntington’s disease.

For more information about these trials, please contact Jamie.Sims@uth.tmc.edu or 713-500-7763 or; Brittany.J.Duncan@uth.tmc.edu or call 713-486-3134.

Neurogenic Orthostatic Hypotension

Restore: double-blinded trial on the use of droxidopa for the management of orthostatic hypotension in non-diabetic patients.

For more information about this trial, please contact Brittany.J.Duncan@uth.tmc.edu or call 713-486-3134.

Rapid Eye Movement Sleep Behavior Disorder

An observational study that aims to identify conversion biomarkers for patients with REM sleep behavior disorder.

For more information about this trial, please contact Vanessa.K.Thyne@uth.tmc.edu or call 713-500-7127.

Deep Brain Stimulation

https://www.youtube.com/watch?v=wrzrd4QtVHY&feature=emb_logo

Product Surveillance Registry: prospective, long-term international multi-center registry to monitor the performance of DBS.
Connectivity changes in Essential Tremor: an observational study that aims to elucidate the structural and functional connectivity changes in Essential Tremor after DBS.

For more information about these trials, please contact Tammy.R.Daniele@uth.tmc.edu or call 713-500-7073; Vanessa.K.Thyne@uth.tmc.edu or call 713-500-7127.

Spasticity Management

Product Surveillance Registry: prospective, long-term international multi-center registry to monitor the performance of Intrathecal baclofen pumps (ITB) as targeted drug delivery (TDD).

For more information about these trials, please contact Tammy.R.Daniele@uth.tmc.edu or call 713-500-7073.

Research Staff:

Research Scientist:
Jessika Suescun, MD

Research Coordinators:
Vanessa Thyne, MS
Jamie Sims, BS, CCRP
Brittany J Duncan, BS

Program Manager and Fellowship Coordinator:
Gloria Galvan